Sugemalimab
Sugemalimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target programmed cell death 1 ligand 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 4 | — | 1 | 7 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 2 | 5 | — | — | 6 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | 1 | — | 1 | 4 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 2 | 1 | — | — | 3 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | 1 | 1 | — | 1 | 3 |
| T-cell lymphoma | D016399 | — | — | — | 1 | 1 | — | 1 | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 1 | 1 | — | 1 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | 1 | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | — | 5 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | — | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Analgesia | D000698 | — | — | — | — | — | — | 1 | 1 |
| Immunotherapy | D007167 | — | — | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Emergence delirium | D000071257 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sugemalimab |
| INN | sugemalimab |
| Description | Sugemalimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594535 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 90IQR2I6TR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CD274
CD274
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 334 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use